This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
The Zacks Analyst Blog Highlights: Facebook, Netflix, NextEra Energy, GlaxoSmithKline and T-Mobile US
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Netflix, NextEra Energy, GlaxoSmithKline and T-Mobile US
Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.
Top Research Reports for Facebook, Netflix & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Netflix (NFLX) and NextEra Energy (NEE).
Glaxo Underperforms Industry in a Year: What's in Store?
by Zacks Equity Research
Shares of Glaxo (GSK) lag the industry in a year as generic erosion of some drugs mainly its top-selling drug, Advair offsets strong sales of new drugs.
Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.
Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales
by Zacks Equity Research
Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
by Kinjel Shah
Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down
by Zacks Equity Research
Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.
Theravance Pipeline Strong, Dependence on Yupelri a Concern
by Zacks Equity Research
Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.
Glaxo (GSK) Misses Earnings & Revenue Estimates in Q4
by Zacks Equity Research
Glaxo misses both earnings and sales estimates in the fourth quarter of 2019. The company initiates separation program to split itself into two standalone units. Stock down.
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter, which is partially offset by lower royalties from Relvar/Breo Ellipta.
Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the fourth quarter.
Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of the HIV franchise and the uptake of Yescarta along with pipeline updates, when Gilead (GILD) reports fourth-quarter 2019 results.
Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down
by Zacks Equity Research
Pfizer (PFE) misses estimates for fourth-quarter earnings and sales. Loss of patent protection for key drug Lyrica in 2019 hurts sales significantly.
Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma
by Zacks Equity Research
Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU
by Kinjel Shah
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
by Zacks Equity Research
Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.
Should Value Investors Pick GlaxoSmithKline (GSK) Stock?
by Zacks Equity Research
Is GlaxoSmithKline (GSK) a great pick from the value investor's perspective right now? Read on to know more.
Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review
by Zacks Equity Research
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View
by Zacks Equity Research
Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.
Glaxo Files Marketing Application for Fostemsavir in Europe
by Zacks Equity Research
Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Gilead (GILD) Inks License Deal with Xencor for HIV Candidate
by Zacks Equity Research
Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.